Pyxis Oncology raises ~$50M in private placement of shares and pre-funded warrants

Pyxis Oncology, Inc.

Gross proceeds of ~$50M from 8.85M shares at $4.78 and pre-funded warrants for 1.61M shares at $4.779.
Participants include Deep Track Capital, Ridgeback Capital, Blue Owl Healthcare, Laurion Capital, and StemPoint Capital.
Proceeds to fund development of lead ADC candidate PYX-201 for solid tumors and for working capital.
Private placement expected to close on or about Feb 29, 2024; registration statement to be filed by Mar 27, 2024.
Leerink Partners serving as lead placement agent; LifeSci Capital as co-placement agent.

item 1.01 item 3.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Pyxis Oncology, Inc. entered into Registration Rights Agreement with the Purchasers (effective 2024-02-26).

Action: entry
Counterparty: the Purchasers
Effective: 2024-02-26

Exact text from the filing

On February 26, 2024, the Company entered into a registration rights agreement (the “Registration Rights Agreement”) with the Purchasers, pursuant to which the Company agreed to register for resale the Shares and the Pre-Funded Warrant Shares held by the Purchasers (the “Registrable Securities”).

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Pyxis Oncology, Inc. entered into Securities Purchase Agreement with certain institutional and accredited investors valued at approximately $50 million (effective 2024-02-26).

Action: entry
Agreement: equity purchase
Counterparty: certain institutional and accredited investors
Value: approximately $50 million
Effective: 2024-02-26

Exact text from the filing

On February 26, 2024, Pyxis Oncology, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) for a private placement (the “Private Placement”) with certain institutional and accredited investors (each, a “Purchaser” and collectively, the “Purchasers”).

View on SEC.gov

747 material agreements filed in the last 30 days. Browse all material agreements →

Pyxis Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-021643

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.